<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03785288</url>
  </required_header>
  <id_info>
    <org_study_id>20163</org_study_id>
    <nct_id>NCT03785288</nct_id>
  </id_info>
  <brief_title>Vaginal Cuff Brachytherapy Fractionation Study</brief_title>
  <official_title>A Randomized Phase III Trial of Two Standard Dose Fractionation Regimes for Adjuvant Vaginal Brachytherapy in Early Stage Endometrial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Timothy Showalter, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see the effects of two different standard of care treatments&#xD;
      of endometrial cancer on sexual dysfunction. This study will compare two standard of care&#xD;
      treatments: HDR (high dose radiation) vaginal brachytherapy 3 fractions of 7 Gy (Arm 1) to&#xD;
      HDR vaginal brachytherapy 6 fractions of 4Gy (Arm 2) for early stage endometrial cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are randomized to Arm 1: HDR vaginal brachytherapy 7 Gy in 3 fractions prescribed at&#xD;
      5mm. Radiation delivered 4-12 weeks after surgery OR Arm 2: HDR vaginal brachytherapy 4Gy in&#xD;
      6 fractions prescribed at the cylinder surface. Radiation delivered 4-12 weeks after surgery.&#xD;
      Participants in both arms will receive standard vaginal dilator for use after treatment (to&#xD;
      promote healing). 1 and 2 year follow up assessments are performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 17, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study will compare two standard of care treatments: HDR vaginal brachytherapy 3 fractions of 7Gy (Arm 1) to HDR vaginal brachytherapy 6 fractions of 4Gy (Arm 2) for early stage endometrial cancer.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Female Sexual Function Index (FSFI)</measure>
    <time_frame>1 year</time_frame>
    <description>Using the FSFI, compare patient reported sexual dysfunction at 1 year after completion of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Preference Option Randomized Design (PORD)</measure>
    <time_frame>1 year</time_frame>
    <description>Assessing the comparative effectiveness of receiving HDR vaginal brachytherapy on Arm B or Arm A for early stage endometrial cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vaginal Length Measurement</measure>
    <time_frame>1 year</time_frame>
    <description>Using vaginal dilator compare patient vaginal measurement 1 year after completion of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaginal Length Measurement</measure>
    <time_frame>2 years</time_frame>
    <description>Using vaginal dilator compare patient vaginal measurement 2 years after completion of treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">258</enrollment>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>HDR VBT 3 fxs of 7Gy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 1: HDR vaginal brachytherapy 3 fractions of 7Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HDR VBT 6 fxs of 4Gy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 2: HDR vaginal brachytherapy 6 fractions of 4Gy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>HDR vaginal brachytherapy</intervention_name>
    <description>Arm 1: HDR vaginal brachytherapy 7 Gy in 3 fractions ; Arm 2: HDR vaginal brachytherapy 4 Gy in 6 fractions</description>
    <arm_group_label>HDR VBT 3 fxs of 7Gy</arm_group_label>
    <arm_group_label>HDR VBT 6 fxs of 4Gy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willingness and ability to provide written informed consent and to comply with the&#xD;
             study protocol as judged by the investigator.&#xD;
&#xD;
          -  Surgery consisted of Total Abdominal or Laparoscopic Hysterectomy and Bilateral&#xD;
             Salpingo Oophorectomy (TH-BSO) with or without lymph node dissection.&#xD;
&#xD;
          -  Subject must have FIGO Stage I-II (grade 1-3) pathologically proven (histologic)&#xD;
             endometrioid cancer, including all subtypes. Serous, clear cell, and carcinosarcoma&#xD;
             histologic pathologies are allowed.&#xD;
&#xD;
          -  Subjects must have no measurable disease after surgery.&#xD;
&#xD;
          -  ECOG Performance Status of 0-2&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Subject must have a life expectancy ≥ 12 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Disease of more advanced stage (FIGO stage III-IV) or disease for which adjuvant&#xD;
             external beam radiation therapy or chemotherapy is indicated&#xD;
&#xD;
          -  Patients with a history of prior pelvic radiation therapy or if additional pelvic&#xD;
             radiation therapy is planned&#xD;
&#xD;
          -  Subjects who have not recovered from side effects of agents administered more than 4&#xD;
             weeks prior to the on-study date&#xD;
&#xD;
          -  Subjects that require &gt; 14 weeks between surgery and initiation of radiotherapy on&#xD;
             study&#xD;
&#xD;
             * Subjects who do not meet this criteria may still be eligible. The UVA Coordinating&#xD;
             Center and Overall Study PI will review each case and inform the site of the approval&#xD;
             decision.&#xD;
&#xD;
          -  Subjects who are receiving any investigational agents or have had any investigational&#xD;
             agent within the 30 days prior to the on-study date&#xD;
&#xD;
          -  Subject is unable or unwilling to participate in a study-related procedure&#xD;
&#xD;
          -  Pregnant and breastfeeding women are excluded from this study&#xD;
&#xD;
          -  Subject is a prisoner&#xD;
&#xD;
          -  A serious uncontrolled medical disorder that in the opinion of the Investigator would&#xD;
             impair the ability of the subject to receive protocol therapy.&#xD;
&#xD;
          -  Subjects with a history of evidence upon physical examination of central nervous&#xD;
             system disease including primary brain tumor, seizures not controlled with standard&#xD;
             medical therapy, any brain metastases, or history of cerebrovascular accident&#xD;
             (stroke), transient ischemic attack, or subarachnoid hemorrhage within six months of&#xD;
             study entry&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy Showalter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Britnee Ochabski</last_name>
    <phone>(434) 924-9969</phone>
    <email>BLO4E@hscmail.mcc.virginia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amy Smith</last_name>
    <email>Ajb6bb@hscmail.mcc.virginia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Maryland Medical Center (UMMC)</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ermiece Straub</last_name>
      <phone>410-328-8018</phone>
      <email>ermiece.straub@umm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Caitlin Eggleston</last_name>
      <phone>410-328-7586</phone>
      <email>caitlineggleston@umm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Pranshu Mohindra, MD, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elizabeth Nichols, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jack J Hong, MD, FACRO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sally Cheston, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Bingham</last_name>
      <phone>315-464-3603</phone>
      <email>BinghamE@upstate.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lindsay Noah-Vermillion</last_name>
      <email>noahverl@upstate.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Brittany Simone, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy Showalter, MD</last_name>
      <email>TNS3B@hscmail.mcc.virginia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Song Wood</last_name>
      <email>STW2G@hscmail.mcc.virginia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kara Romano, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Timothy Showalter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leigh Cantrell, MD, MSPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 15, 2018</study_first_submitted>
  <study_first_submitted_qc>December 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2018</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Timothy Showalter, MD</investigator_full_name>
    <investigator_title>Principle Investigator-MD Radiation Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

